MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Recruiting
Masonic Cancer Center, University of Minnesota
2018-12-18
This is a phase II study of FDA-approved CAR-T products for patients with hematologic
malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall
remission rate, safety events and other endpoints will be calculated for Arm A and B
separately.
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
Terminated
Jazz Pharmaceuticals
Phase 2
2019-10-04
This is a prospective, open-label, single-arm study evaluating the safety and efficacy of
defibrotide for the prevention of CAR-T-associated neurotoxicity in subjects with relapsed or
refractory diffuse large B-cell lymphoma (DLBCL) receiving Yescarta.
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Suspended
National Cancer Institute (NCI)
Phase 2
2020-03-04
This phase II trial studies how well anakinra works in preventing severe chimeric antigen
receptor T-cell-related encephalopathy syndrome after chimeric antigen receptor T-cell
therapy in patients with large B-cell lymphoma that has come back or has not responded to
treatment. Immunosuppressive therapy, such as anakinra, is used to decrease the body?s immune
response, which may prevent severe chimeric antigen receptor T-cell-related encephalopathy
syndrome.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
